文献速递前列腺癌男科与性医学

非转移性前列腺癌治疗后抗抑郁药处方的变化与趋势:基于人群的队列研究

Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.
PubMed 文献 · Eur Urol · 2018-09-18

该研究基于加拿大安大略省2002至2009年人群数据,纳入≥66岁接受手术、放疗或监测的非转移性前列腺癌患者,并与一般人群对照匹配。治疗后一年抗抑郁药处方比例从7.7%升至10.5%;手术和放疗后5年内抗抑郁药接收风险增加,监测后未增加。提示手术或放疗后需关注心理影响。

要点

  • 非转移性前列腺癌治疗后一年抗抑郁药处方比例由7.7%升至10.5%。
  • 手术或放疗后5年内抗抑郁药接收风险显著增加,监测后未增加。
  • 应关注前列腺癌治疗后生存期的心理影响。

核心结论

  • 初始接受手术或放疗的非转移性前列腺癌患者治疗后抗抑郁药接收风险增加,初始监测者未增加。

研究设计与样本

  • 基于人群的队列研究,利用关联行政数据,纳入≥66岁接受手术(n=4952)、放疗(n=4994)或监测(n=2136)的非转移性前列腺癌患者,并与一般人群对照(n=57127)匹配。

主要发现

  • 治疗前一年7.7%的患者接受抗抑郁药处方,治疗后一年增至10.5%。
  • 手术後5年内抗抑郁药接收的比值比OR 1.49(95%CI 1.35-1.64;p≤0.0001)。
  • 放疗後5年内抗抑郁药接收的比值比OR 1.33(95%CI 1.21-1.47;p≤0.0001)。
  • 监测後5年内抗抑郁药接收的比值比OR 1.15(95%CI 0.94-1.41;p=0.16)。

临床怎么用

  • 对接受手术或放疗的非转移性前列腺癌患者,在生存期随访中应考虑心理影响并评估抗抑郁药使用。

局限性

  • 回顾性设计和行政数据库使用可能导致选择偏倚和错分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psychological distress is prevalent among men with prostate cancer (PCa). However, the variation in antidepressant use among individuals throughout the survivorship period is unknown. We sought to examine the variation and trends in receipt of antidepressants after PCa treatment, among patients with nonmetastatic PCa. Using population-based linked administrative data, we identified men ≥66 yr old who underwent surgery (n=4952), radiotherapy (n=4994), or surveillance (n=2136), and these men were matched to general population controls (n=57127). One year prior to PCa treatment, 7.7% of men received an antidepressant prescription, which increased to 10.5% in the year after treatment. In difference-in-differences analysis, adjusted for demographic and health characteristics, men had increased odds of antidepressant receipt up to 5 yr after surgery (odds ratio [OR] 1.49; 95% confidence interval [CI] 1.35-1.64; p≤0.0001) or radiotherapy (OR 1.33; 95% CI 1.21-1.47; p≤0.0001). Men did not have an increased risk of antidepressant receipt up to 5 yr after surveillance (OR 1.15; 95% CI 0.94-1.41; p=0.16). Limitations include the potential for selection bias and misclassification due to the retrospective design of the study and the use of administrative databases. Thus, men with nonmetastatic PCa who initially receive surgery or radiotherapy, but not those who initially undergo surveillance, have an increased risk of antidepressant receipt after treatment. PATIENT SUMMARY: In this report, we examined antidepressant prescription for men after treatment of nonmetastatic prostate cancer across the entire population of men ≥66 yr in Ontario, Canada, from 2002 to 2009. For men diagnosed with nonmetastatic prostate cancer, the risk of antidepressant receipt at 5 yr after treatment was significantly increased after surgery or radiotherapy, but not after surveillance. Providers and patients should consider the psychological effects of prostate cancer treatment during the survivorship period.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Matta R, Wallis CJD, Goldenberg MG, et al. Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study. Eur Urol. 2018. PMID: 30241972. doi:10.1016/j.eururo.2018.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。